Introduction
Mitochondrial disorders encompass clinical phenotypes associated with abnormalities of oxidative phosphorylation. Due to the dual genetic control of mitochondria, these diseases can either be caused by primary alterations of the mitochondrial DNA (mtDNA), or by mutations in nuclear genes affecting mitochondrial function. 35 Important advances have been made regarding the genetic background of mitochondrial disorders in the past decade. 7, 20 Among the diseases affecting mitochondrial tRNA (mt tRNA) genes, two common syndromes are the MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), and myoclonic epilepsy with ragged-red fibers syndrome (MERRF). 6, 23 The clini- The mitochondrial DNA A3243G transition is a fairly common mutation which often associates with a MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) phenotype, however, a broad variety in the associated clinical picture has also been described. The patient reported here developed a generalized seizure at age 12, which was followed by bilateral hearing loss and occasional fatigue. The maternal inheritance pattern of hearing loss pointed to a possible mitochondrial origin, which was confirmed by molecular analysis of the mitochondrial DNA, revealing a heteroplasmic A3243G transition. Interestingly, muscle biopsy showed ragged-red fibers in the proband, which is unusual in the deafness-associated forms of this mitochondrial disorder. In addition to hearing impairment in four generations of the family, fatal cerebral embolization in the mother and fatal heart attack in the maternal grandmother (both at age 33) also occurred. Maternally inherited hearing loss can be part of a syndrome, or can present as non-syndromic isolated hearing impairment. 8 In the classic mitochondrial diseases, such as Kearns-Sayre syndrome, MELAS syndrome and MERRF syndrome, hearing loss is often part of the clinical signs. 14 The maternally inherited diabetes and deafness syndrome (MIDD) is also caused by mtDNA mutations, mostly point mutations affecting mt tRNA genes. In the majority of the cases the same mutation (mtDNA A3243G) is responsible for the disease as for the systemic MELAS syndrome. 28, 32 Non-syndromic hearing loss and ototoxic hearing deficit may also be due to mutations affecting mitochondrial tRNA or rRNA genes.
Here we report a 13-year-old boy in whom a mild phenotypic presentation was associated with the A3243G tRNA Leu(UUR) mutation. The main clinical features were a seizure disorder and mild bilateral sensorineural hearing loss. Early, lethal complications of thrombophilia were present in the maternal family members in addition to sensorineural hearing loss. These are unusual manifestations of this mutation.
Patients and methods

Case report
Our patient was born by vaginal delivery, following drug-assisted conception after 13 years of infertility, at week 36 of gestation, with 3050 g. He received exchange blood transfusion in the neonatal period due to Rh incompatibility. His psychomotor development was age-appropriate. At 12 years he suffered a generalized seizure (Grand Mal) with positive EEG (generalized paroxysmal activity). Valproic acid therapy was initiated and he remained asymptomatic. By 13 years, bilateral hearing loss developed. Audiology showed mild sensorineural hearing loss on his right and moderate deficit on his left ear. Besides the hearing loss, he also complained of fatigue, and transient muscular pain. His follow-up EEG recording showed generalized paroxysmal activity, a brain MRI revealed no focal abnormality.
The mother of the proband also suffered from hearing impairment. She died of cerebral embolism shortly after her delivery at the age of 33. The maternal grandmother, who also had hypacusis, suffered a fatal heart attack at the age of 33. The maternal great-grandmother had bilateral deafness as the only symptom.
Mitochondrial DNA analysis
DNA was extracted from peripheral blood leukocytes using a routine desalting method. The most common mitochondrial DNA point mutations were evaluated in addition to the mtDNA mutations known to be associated with maternally inherited hearing loss (A1555G, A3243G, A7445G, 7472insC, T7511C). The entire mt tRNA Leu(UUR) gene was also sequenced. This is one of the known mutational hotspots associated with the MELAS syndrome (A3243G, A3252G, G3256T, A3260G, T3271C, T3291C). For amplification and sequencing of the MELAS mutational hotspot the following primers were designed: forward primer, AAA TGA TAT CAT CTC AAC TTA G; reverse primer, GAT GGT GAG AGC TAA GGT C. The PCR amplifications were performed on MJR PTC 200 thermal cyclers with a similar protocol for each mutation investigated. The PCR products were sequenced in both directions with an ABI Prism 3100 Avant Genetic Analyzer using the dye termination technique according to the instructions of the manufacturer (Applied Biosystems, Foster City, CA, USA). For a semiquantitative analysis of the degree of heteroplasmy a restriction fragment length polymorphism (RFLP) assay was designed. The mtDNA between nucleotides 2695-4724 was amplified by polymerase chain reaction (PCR) and digested with Bsp120I restriction digestion enzyme for the estimation of the degree of heteroplasmy. The wild-type sequence already contains an obligatory Bsp120I cleavage site in order to test the fidelity of the assay. In case of a mutation, replacement of adenine (A) with guanine (G) at nucleotide position 3243 creates a new cleavage site by the restriction enzyme. After digestion the PCR fragments were transferred to a 0.8% agarose gel and visualized by ethidium bromide stain. The degree of heteroplasmy was estimated according to the intensity of the bands.
Informed consent was obtained from the father and from the patient to all procedures performed.
Results
The maternal inheritance pattern of hearing impairment prompted a mtDNA evaluation. The mitochondrial DNA analysis from peripheral blood leukocytes of our proband showed a heteroplasmic A-G point mutation at nucleotide position 3243 in the tRNA Leu(UUR) gene (Figure 1) Leu(UUR) gene and of the other known point mutations associated with maternally inherited hearing loss gave normal results. During direct sequencing of the mitochondrial 12S rRNA of the proband we detected a homoplasmic A-G substitution at nucleotide position 1438, a known polymorphism with no pathological relevance attributed to it so far. During restriction enzyme digestion of the mtDNA fragment containing the mutation, we detected the wild-type sequence in approximately 60% and the mutated sequence in approximately 40% (Figure 1) .
Parallel to the genetic evaluations, a muscle biopsy was performed to explore his muscular weakness. In the muscle biopsy specimen of our proband (Figure 2 ) several ragged-red fibers (RRF) could be identified with modified Gömöri trichrome staining (approximately 20% of the fibers). Succinate dehydrogenase (SDH) staining also showed RRFs, however, strong SDH-reactive blood vessels, characteristic for MELAS, were not detected. The cytochrome oxidase method revealed normal enzyme activity in the majority of the fibers, but cytochrome oxidase-negative ones were found occasionally. The typical features seen in the muscle biopsy specimen supported the presence of mitochondrial myopathy.
Due to the above findings, lactate levels and oral glucose tolerance was tested in the patient. No lactic acidosis, or elevated blood glucose level, nor glycosuria could be detected in repeated evaluations. Additionally, blood glucose and lactate levels were also within normal limits during the oral glucose tolerance test.
The literature suggested that patients with seizures associated with the A3243G mutation may respond adversely to valproic acid. 17 Consequently, the proband was switched to carbamazepine therapy, but tremors developed. Therefore, lamotrigine was initiated and carbamazepine discontinued. He remains symptom-free on 2x100 mg/day of lamotrigine.
A trial of coenzyme Q10 therapy for 2 months (3x40 mg/day) was also initiated. 4, 13 However, despite of this effort his hearing loss mildly advanced.
Discussion
According to recent epidemiological studies, mitochondrial disorders are far more frequent than previously believed. Their prevalence is estimated to be 1:8500. 2 Thus, they represent a significant group of metabolic diseases. The phenotypic expression of a mitochondrial molecular defect can be influenced by multiple factors, such as the proportion of the mutation in different cells and tissues (the degree of heteroplasmy), and the nuclear genetic background of a given patient. Additionally, mitochondrial DNA haplotype and environmental factors are also known to play a crucial role. 8, 31, 35 Consequently, the disorders inherited through the mtDNA can associate with an extremely variable clinical phenotype. 1, 22 These may remain undiagnosed in case they present with isolated, single symptoms, failing to show the full-blown clinical picture. Among the disorders caused by alterations of the mitochondrial genome, special attention
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KOMLÓSI et al should be given to mitochondrial tRNA gene mutations due to their frequency. A single point mutation affecting a mitochondrial tRNA gene may alter the molecular cellular processes at several different levels: the appropriate mRNA synthesis or translation can be defective, or a mutation influencing the conformation of tRNAs may eventually lead to deficient mitochondrial protein synthesis and, consequently, disturbed oxidative phosphorylation. 5 The MELAS syndrome is typically a multisystemic disorder presenting in childhood. 11, 25 However, both the appearance of symptoms, as well as the phenotypic spectrum shows a great variety. 3, 21, 27 The classic, fully developed clinical picture is dominated by the tonic-clonic seizures, recurrent headaches, episodic vomiting, visual impairment, later the typical stroke-like episodes with transient hemiparesis. Analysis of extended families carrying the A3243G MELAS mutation showed several oligosymptomatic members. In the lack of stroke-like episodes, the most common symptoms were sensorineural hearing loss, 8 diabetes, 9 nephropathy, 3 myopathy, 12 cardiomyopathy, 29 cerebellar signs and mental retardation. Among the carriers, asymptomatic members are also known to exist. 3 Previously, we have reported on the first Hungarian MELAS case with a classic, fully developed phenotype. 16 Our patient presented here, however, had only one episode of generalized seizure. His main symptom was a slowly deteriorating sensorineural hearing loss. During audiological examination, which showed mild to moderate sensorineural hearing loss, a positive maternal family history was revealed imposing the possibility of mtDNA-inherited hearing impairment. His fatigue and muscle weakness in combination with the hypacusis also pointed to mitochondrial origin.
The A-G transition at np 3243 of the mtDNA affects the tRNA Leu(UUR) gene. 10, 15 The mutation is observed in a heteroplasmic state in patients. 18, 19, 24 In the mtDNA obtained from peripheral leukocytes of our patient, the wild-type sequence was detected in approx. 60%, while the mutated sequence was 40%; there is no data available concerning the degree of heteroplasmy in other tissues. It is known that the A3243G mtDNA mutation is also associated with the maternally inherited diabetes and deafness syndrome (MIDD).
32, 28 The sensorineural hearing loss associated with this mutation is proposed to be caused by the dysfunction of the stria vascularis and spiral ganglion cells of the inner ear. 30 According to another examination, the mutation preferentially affects these inner ear structures, and deafness can occur even when the proportion of the A3243G mutation is low. 34 However, the absence of diabetes and the presence of variable other symptoms in the maternal family members does not correspond to the MIDD syndrome in our case.
Parallel to the molecular genetic studies, a muscle biopsy was performed and the specimen was evaluated for overall histology and histochemistry. Both the modified Gömöri-trichrome staining, and the SDH staining revealed ragged-red fibers (RRF), a hallmark of defective mitochondria. On the other hand, strong SDH-reactive blood vessels, characteristic for MELAS syndrome, could not be detected in the specimen of our patient.
Our patient's final diagnosis and the maternal inheritance pattern of the hearing loss suggest that the audiological deficit in the family was likely due to the mitochondrial DNA A3243G transition. However, the thrombophilic manifestations -such as the fatal stroke-like attack of the mother at the age of 33 and the fatal heart infarct of the grandmother incidentally also at the age of 33 -are not known as usual phenotypic presentations of this mutation. The clinical presentation of our proband and his maternal family members suggest that this known mtDNA defect may associate with unusual phenotypes in the Hungarian population.
